245 results on '"Delaloge, S"'
Search Results
2. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
3. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
4. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
5. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
6. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
7. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
8. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
9. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
11. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
12. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
13. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
14. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
15. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
16. 38P Single molecule localization microscopy for extracellular vesicles detection in cancer
17. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
18. 467P Dose escalation of TAS-117 in patients with advanced solid tumors
19. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
20. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
21. 225P Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN)
22. 174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
23. 135P Real-time genotyping-based breast cancer risk assessment in MyPeBS, an international randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS)
24. 167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
25. Reply to ‘The potential and perils of observational studies’ by M. Buyse et al.
26. Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting
27. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
28. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
29. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
30. 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers
31. 559TiP A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN inactivating mutations
32. 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
33. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
34. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
35. 1734P Early impact of a personalized lung cancer interception program for heavy smokers
36. 1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
37. 1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group
38. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
39. Pharmacokinetic interaction involving fenofibrate and everolimus
40. Reply to the letter to the editor ‘Treating breast cancer with trabectedin: a new arsenal’ by L. Malik
41. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
42. 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
43. Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
44. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
45. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
46. Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
47. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
48. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement†
49. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
50. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.